Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Clinical features, diagnosis, and management of patients with Fabry disease with cardiac disease

Sherif F Nagueh, MD, FACC, FAHA, FASE
Section Editor
William J McKenna, MD
Deputy Editor
Susan B Yeon, MD, JD, FACC


Fabry disease (MIM 300644, also known as angiokeratoma corporis diffusum, ceramide trihexosidosis, or Anderson-Fabry disease) is an X-linked glycolipid storage disease [1,2]. It is caused by deficient activity of the lysosomal enzyme alpha-galactosidase A, resulting in the accumulation of globotriaosylceramide in lysosomes in multiple cell types throughout the body.

While males are more severely diseased, most heterozygous females are also affected, though usually at a later age [3-6].

Clinical manifestations are variable and include cutaneous, corneal, cardiac, renal, and neurologic manifestations. The typical presentation occurs in children who suffer from peripheral neuropathy of the hands and feet, nausea, and abdominal pain. However, diagnosis is frequently missed due to the rarity of the disease. Other characteristic features include reduced sweating and the cutaneous lesions of angiokeratoma corporis (picture 1 and picture 2), which are vascular papules typically distributed in the inguinal, hip, and periumbilical areas. These become more prominent with age. Manifestations of renal disease include proteinuria and progressive renal insufficiency, which sometimes result in end-stage renal disease. In adults, there is progressive cardiac, renal, and cerebral involvement (transient ischemic attacks and strokes), which are the major causes of death associated with Fabry disease. (See "Clinical features and diagnosis of Fabry disease".)

The cardiac features of Fabry disease and the incidence of unexpected Fabry disease in patients with otherwise unexplained left ventricular hypertrophy will be reviewed here. The general clinical manifestations and treatment of Fabry disease are discussed separately. (See "Clinical features and diagnosis of Fabry disease" and "Treatment of Fabry disease".)


Clinical features — Cardiovascular manifestations of Fabry disease include left ventricular hypertrophy (LVH), aortic and mitral regurgitation, conduction defects, coronary artery disease, hypertension, and aortic root dilation [6-11]. The right ventricle is also often hypertrophied [12]. Many patients with cardiac involvement are asymptomatic, whereas others present with angina, dyspnea, palpitations, or syncope. Rare patients have advanced heart failure symptoms in the setting of unexplained LVH and generally normal LV ejection fraction (LVEF).


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Dec 2016. | This topic last updated: Thu Jul 07 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Desnick RJ, Brady R, Barranger J, et al. Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med 2003; 138:338.
  2. Eng CM, Ashley GA, Burgert TS, et al. Fabry disease: thirty-five mutations in the alpha-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 1997; 3:174.
  3. Wang RY, Lelis A, Mirocha J, Wilcox WR. Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 2007; 9:34.
  4. Weidemann F, Niemann M, Sommer C, et al. Interdisciplinary approach towards female patients with Fabry disease. Eur J Clin Invest 2012; 42:455.
  5. Kampmann C, Baehner F, Whybra C, et al. Cardiac manifestations of Anderson-Fabry disease in heterozygous females. J Am Coll Cardiol 2002; 40:1668.
  6. O'Mahony C, Elliott P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis 2010; 52:326.
  7. Nagueh SF. Fabry disease. Heart 2003; 89:819.
  8. Kampmann C, Baehner F, Ries M, Beck M. Cardiac involvement in Anderson-Fabry disease. J Am Soc Nephrol 2002; 13 Suppl 2:S147.
  9. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38:750.
  10. Patel MR, Cecchi F, Cizmarik M, et al. Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J Am Coll Cardiol 2011; 57:1093.
  11. Gambarin FI, Disabella E, Narula J, et al. When should cardiologists suspect Anderson-Fabry disease? Am J Cardiol 2010; 106:1492.
  12. Niemann M, Breunig F, Beer M, et al. The right ventricle in Fabry disease: natural history and impact of enzyme replacement therapy. Heart 2010; 96:1915.
  13. Kampmann C, Linhart A, Baehner F, et al. Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 2008; 130:367.
  14. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 2001; 38:769.
  15. Wu JC, Ho CY, Skali H, et al. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur Heart J 2010; 31:1088.
  16. Yousef Z, Elliott PM, Cecchi F, et al. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J 2013; 34:802.
  17. Nakao S, Takenaka T, Maeda M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333:288.
  18. Sachdev B, Takenaka T, Teraguchi H, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105:1407.
  19. Linhart A, Palecek T, Bultas J, et al. New insights in cardiac structural changes in patients with Fabry's disease. Am Heart J 2000; 139:1101.
  20. Linhart A, Elliott PM. The heart in Anderson-Fabry disease and other lysosomal storage disorders. Heart 2007; 93:528.
  21. Chimenti C, Padua L, Pazzaglia C, et al. Cardiac and skeletal myopathy in Fabry disease: a clinicopathologic correlative study. Hum Pathol 2012; 43:1444.
  22. Weidemann F, Strotmann JM, Niemann M, et al. Heart valve involvement in Fabry cardiomyopathy. Ultrasound Med Biol 2009; 35:730.
  23. Chimenti C, Morgante E, Tanzilli G, et al. Angina in fabry disease reflects coronary small vessel disease. Circ Heart Fail 2008; 1:161.
  24. Shah JS, Hughes DA, Sachdev B, et al. Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease. Am J Cardiol 2005; 96:842.
  25. Ikari Y, Kuwako K, Yamaguchi T. Fabry's disease with complete atrioventricular block: histological evidence of involvement of the conduction system. Br Heart J 1992; 68:323.
  26. Mehta J, Tuna N, Moller JH, Desnick RJ. Electrocardiographic and vectorcardiographic abnormalities in Fabry's disease. Am Heart J 1977; 93:699.
  27. Pochis WT, Litzow JT, King BG, Kenny D. Electrophysiologic findings in Fabry's disease with a short PR interval. Am J Cardiol 1994; 74:203.
  28. Blum A, Ashkenazi H, Haromankov I, et al. First-degree atrioventricular block and restrictive physiology as cardiac manifestations of Fabry's disease. South Med J 2003; 96:212.
  29. Linhart A, Kampmann C, Zamorano JL, et al. Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey. Eur Heart J 2007; 28:1228.
  30. Barbey F, Qanadli SD, Juli C, et al. Aortic remodelling in Fabry disease. Eur Heart J 2010; 31:347.
  31. Kampmann C, Wiethoff CM, Martin C, et al. Electrocardiographic signs of hypertrophy in fabry disease-associated hypertrophic cardiomyopathy. Acta Paediatr Suppl 2002; 91:21.
  32. Becker AE, Schoorl R, Balk AG, van der Heide RM. Cardiac manifestations of Fabry's disease. Report of a case with mitral insufficiency and electrocardiographic evidence of myocardial infarction. Am J Cardiol 1975; 36:829.
  33. Coats CJ, Parisi V, Ramos M, et al. Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease. Am J Cardiol 2013; 111:111.
  34. Shanks M, Thompson RB, Paterson ID, et al. Systolic and diastolic function assessment in fabry disease patients using speckle-tracking imaging and comparison with conventional echocardiographic measurements. J Am Soc Echocardiogr 2013; 26:1407.
  35. Zamorano J, Serra V, Pérez de Isla L, et al. Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease. Eur J Echocardiogr 2011; 12:671.
  36. Pieroni M, Chimenti C, Ricci R, et al. Early detection of Fabry cardiomyopathy by tissue Doppler imaging. Circulation 2003; 107:1978.
  37. Krämer J, Niemann M, Liu D, et al. Two-dimensional speckle tracking as a non-invasive tool for identification of myocardial fibrosis in Fabry disease. Eur Heart J 2013; 34:1587.
  38. Kawano M, Takenaka T, Otsuji Y, et al. Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry's disease. Am J Cardiol 2007; 99:261.
  39. Weidemann F, Breunig F, Beer M, et al. The variation of morphological and functional cardiac manifestation in Fabry disease: potential implications for the time course of the disease. Eur Heart J 2005; 26:1221.
  40. Pieroni M, Chimenti C, De Cobelli F, et al. Fabry's disease cardiomyopathy: echocardiographic detection of endomyocardial glycosphingolipid compartmentalization. J Am Coll Cardiol 2006; 47:1663.
  41. Kounas S, Demetrescu C, Pantazis AA, et al. The binary endocardial appearance is a poor discriminator of Anderson-Fabry disease from familial hypertrophic cardiomyopathy. J Am Coll Cardiol 2008; 51:2058.
  42. Koskenvuo JW, Engblom E, Kantola IM, et al. Echocardiography in Fabry disease: diagnostic value of endocardial border binary appearance. Clin Physiol Funct Imaging 2009; 29:177.
  43. Mundigler G, Gaggl M, Heinze G, et al. The endocardial binary appearance ('binary sign') is an unreliable marker for echocardiographic detection of Fabry disease in patients with left ventricular hypertrophy. Eur J Echocardiogr 2011; 12:744.
  44. Moon JC, Sheppard M, Reed E, et al. The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease. J Cardiovasc Magn Reson 2006; 8:479.
  45. De Cobelli F, Esposito A, Belloni E, et al. Delayed-enhanced cardiac MRI for differentiation of Fabry's disease from symmetric hypertrophic cardiomyopathy. AJR Am J Roentgenol 2009; 192:W97.
  46. Weidemann F, Niemann M, Breunig F, et al. Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment. Circulation 2009; 119:524.
  47. Niemann M, Herrmann S, Hu K, et al. Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment. JACC Cardiovasc Imaging 2011; 4:592.
  48. Moon JC, Sachdev B, Elkington AG, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium. Eur Heart J 2003; 24:2151.
  49. Elliott PM, Kindler H, Shah JS, et al. Coronary microvascular dysfunction in male patients with Anderson-Fabry disease and the effect of treatment with alpha galactosidase A. Heart 2006; 92:357.
  50. Weidemann F, Breunig F, Beer M, et al. Improvement of cardiac function during enzyme replacement therapy in patients with Fabry disease: a prospective strain rate imaging study. Circulation 2003; 108:1299.
  51. Spinelli L, Pisani A, Sabbatini M, et al. Enzyme replacement therapy with agalsidase beta improves cardiac involvement in Fabry's disease. Clin Genet 2004; 66:158.
  52. Banikazemi M, Bultas J, Waldek S, et al. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 2007; 146:77.
  53. Morita H, Larson MG, Barr SC, et al. Single-gene mutations and increased left ventricular wall thickness in the community: the Framingham Heart Study. Circulation 2006; 113:2697.
  54. Ommen SR, Nishimura RA, Edwards WD. Fabry disease: a mimic for obstructive hypertrophic cardiomyopathy? Heart 2003; 89:929.
  55. Chimenti C, Pieroni M, Morgante E, et al. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy. Circulation 2004; 110:1047.
  56. Namdar M, Steffel J, Vidovic M, et al. Electrocardiographic changes in early recognition of Fabry disease. Heart 2011; 97:485.
  57. Hershberger RE, Lindenfeld J, Mestroni L, et al. Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline. J Card Fail 2009; 15:83.
  58. Liu D, Hu K, Niemann M, et al. Effect of combined systolic and diastolic functional parameter assessment for differentiation of cardiac amyloidosis from other causes of concentric left ventricular hypertrophy. Circ Cardiovasc Imaging 2013; 6:1066.
  59. Thurberg BL, Fallon JT, Mitchell R, et al. Cardiac microvascular pathology in Fabry disease: evaluation of endomyocardial biopsies before and after enzyme replacement therapy. Circulation 2009; 119:2561.
  60. Manohar VA, Moder KG, Edwards WD, Klarich K. Restrictive cardiomyopathy secondary to hydroxychloroquine therapy. J Rheumatol 2009; 36:440.
  61. Weidemann F, Maier SK, Störk S, et al. Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy. Am J Cardiol 2016; 118:264.
  62. WRITING COMMITTEE MEMBERS, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128:e240.
  63. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33:1787.
  64. Heart Failure Society of America, Lindenfeld J, Albert NM, et al. HFSA 2010 Comprehensive Heart Failure Practice Guideline. J Card Fail 2010; 16:e1.
  65. Cantor WJ, Daly P, Iwanochko M, et al. Cardiac transplantation for Fabry's disease. Can J Cardiol 1998; 14:81.
  66. El Dib RP, Nascimento P, Pastores GM. Enzyme replacement therapy for Anderson-Fabry disease. Cochrane Database Syst Rev 2013; :CD006663.
  67. Imbriaco M, Pisani A, Spinelli L, et al. Effects of enzyme-replacement therapy in patients with Anderson-Fabry disease: a prospective long-term cardiac magnetic resonance imaging study. Heart 2009; 95:1103.
  68. Weidemann F, Niemann M, Störk S, et al. Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 2013; 274:331.
  69. Frustaci A, Chimenti C, Ricci R, et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 2001; 345:25.